Effects of sodium on agonist efficacy for G-protein activation in μ-opioid receptor-transfected CHO cells and rat thalamus

British Journal of Pharmacology

Volumn 130, Issue 5, 2000, Pages 987-996

  Selley, Dana E ^a   Cao, Cheng Chun ^b   Liu, Qixu ^b   Childers, Steven R ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Agonist efficacy; G protein; Opioid receptor; Pertussis toxin; Sodium

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MONOVALENT CATION; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; PERTUSSIS TOXIN; POTASSIUM CHLORIDE; SODIUM; SODIUM CHLORIDE; SULFUR 35;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CHO CELL; CONTROLLED STUDY; GENETIC TRANSFECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; THALAMUS;

EID: 0033948088     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703382     Document Type: Article

References (46)

1. ABOOD, M., NOEL, M., CARTER, R. & HARRIS, L. (1995). Evaluation of a series of N-alkyl benzomorphans in cell lines expressing transfected δ and μ-opioid receptors. Biochem. Pharmacol., 50, 851-859.
2. ADAMS, J., PARONIS, C. & HOLTZMAN, S. (1990). Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using β-funaltrexamine. J. Pharmacol. Exp. Ther., 255, 1027-1032.
3. 2 adrenoceptor: evidence for empty receptor stimulation of the adenylate cyclase cascade. Biochem. J., 303, 803-808.
4. AMMER, H. & SCHULZ R. (1993). Alterations in the expression of G-proteins and regulation of adenylate cyclase in human neuroblastoma SH-SY5Y cells chronically exposed to low-efficacy μ-opioids. Biochem. J., 295, 263-271.
5. BREIVOGEL, C.S., SELLEY, D.E. & CHILDERS, S.R. (1997). Acute and chronic effects of opioids on delta and mu receptor activation of G-proteins in NG108-15 and SK-N-SH cell membranes. J. Neurochem., 68, 1462-1472.
6. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J. Biol. Chem., 273, 16865-16873.
7. CARTER, B.D. & MEDZIHRADSKY, F. (1993). Receptor mechanisms of opioid tolerance in SH-SY5Y human neural cells. Mol. Pharmacol., 43, 465-473.
8. CERESA, B.P. & LIMBIRD. L.E. (1994). Mutation of an aspartate residue highly conserved among G-protein-coupled receptors results in nonreciprocal disruption of α2-adrenergic receptor-G-protein interactions: A negative charge at amino acid residue 79 forecasts α2A-adrenergic receptor sensitivity to allosteric modulation by monovalent cations and fully effective receptor, G-protein coupling. Journal of Biol. Chem., 269, 29557-29564.
9. CHEN, V . MESTEK, A., LIU, J., HURLEY, J.A. & YU, L. (1993). Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol. Pharmacol., 44, 8-12.
10. CHILDERS, S.R. (1991). Opioid receptor-coupled second messengers. Life Sci., 48, 1991-2003.
11. CHIU, T., YUNG, L. & WONG, Y. (1996). Inverse agonistic effect of ICI-174,864 on the cloned δ-opioid receptor: role of G-protein and adenylyl cyclase activation. Mol. Pharmacol., 50, 1651-1657.
12. CORBETT, A.D., PATERSON, S J. & KOSTERLITZ, H.W. (1993). Selectivity of ligands for opioid receptors. In [it] Handbook of Experimental Pharmacology: Opioids I. ed. Herz, A. pp. 645-679. Berlin: Springer-Verlag.
13. COSTA, T . LANG, J., GLESS, C. & HERZ, A. (1990). Spontaneous association between opioid receptors and GTP-binding proteins in native membranes: specific regulation by antagonists and sodium ions. Mol. Pharmacol., 37, 383-394.
14. COSTA, T., OGINO, Y., MUNSON, P., ONARAN, H. & RODBARD, D. (1992). Drug efficacy at guanine nucleotide-binding regulatory protein linked receptors: Thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol. Pharmacol., 41, 549-560.
15. EMMERSON, P.J., CLARK, M.J., MANSOUR, A., AKIL, H., WOODS, J.H. & MEDZIHRADSKY, F. (1996). Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the μ opioid receptor. J. Pharmacol. Exp. Ther., 278, 1121-1127.
16. HERKENHAM, M. & PERT, C.B. (1982). Light microscopic localization of brain opiate receptors: A general autoradiographic method which preserves tissue quality. J. Neurosc., 2, 1129-1149.
17. HILF, G & JAKOBS, K.H. (1992). Agonist-independent inhibition of G protein activation by muscarinic acetylcholine receptor antagonists in cardiac membranes. European J. Pharmacol., 225, 245-252.
18. HORSTMAN, D.A , BRANDON, S., WILSON, A.L., GUYER, C.A., CRAGOE, C.A. & LIMBIRD, L.E. (1990). An aspartate conserved among G-protein receptors confers allosteric regulation of alpha(2)-adrenergic receptors by sodium. J. Biol. Chem., 265, 21590-21595.
19. KATO, S., KUKUDA, K., MORIKAWA, H., SHODA, T., MIMA, H. & MORI, K. (1998). Adaptations to chronic agonist-exposure of mu-opioid receptor-expressing Chinese hamster ovary cells. Europ. J. Pharmacol., 345, 221-228.
20. KAUFMAN, D., KEITH, D., ANTON, B., TIAN, J., MAGENDZO, K., NEWMAN, D., TRAN, T., LEE, D., WEN, C., NIA, Y.-R., LUSIS. A & EVANS, C. (1995). Characterization of the murine μ opioid receptor gene. J. Biol. Chem., 270, 15877-15883.
21. + regulation of agonist binding but does not alter receptor-G protein association. Mol. Pharmacol., 44, 380-384.
22. KONG, H., RAYNOR. K., YASUDA, K., MOE, S., PORTOGHESE, P , BELL, G & REISINE, T. (1993b). A single residue, aspartic acid 95, in the δ opioid receptor specifies selective high affinity agonist binding. J. Biol. Chem., 286, 23055-23058.
23. LORENZEN, A., GUERRA, L., VOGT, H. & SCHWABE, U (1996). Interaction of full and partial agonists of the AI adenosine receptor with receptor G protein complexes in rat brain membranes. Mol. Pharmacol., 49, 915-926.
24. MATTHES, H W.D., MALDONADO, R., SIMONIN, F., VALVERDE, O., SLOWE, S., KITCHEN, I., BETORT, K., DIERICH. A., LEMFUR, M. DOLLE, P., TZAVARA, E., HANOUNE, J., ROQUTS, B P & KIEFFER, B.I. (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature, 383, 819-823.
25. MERKOURIS, M., MULLANEY, I., GEORGOUSSI, Z. & MILLIGAN, G. (1997). Regulation of spontaneous activity of the δ-opioid receptor: Studies of inverse agonism in intact cells. J. Neurochem., 69, 2115-2122.
26. MJANGER, E & YAKSH, T L . (1991). Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects intrathecal mu agonists. J. Pharmacol. Exp. Ther., 258, 544-550.
27. MULLANEY, I., CARR, I. & MILLIGAN, G. (1996). Analysis of inverse agonism at the δ opioid receptor after expression in Rat 1 fibroblasts. Biochem. J., 315, 227-234.
28. 1A receptors as a function of receptor:G-protein stoichiometry. Neuropharmacol., 36, 451-459.
29. PACHECO, M.A , WARD, S.J. & CHILDERS, S.R. (1994). Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes. J. Neurochem., 62, 1773-1782.
30. PAK, Y., KOUVELAS, A., SCHEIDLER, M., RASMUSSEN, J , O'DOWD, B. & GEORGE, S (1996). Agonist-induced functional desensitization of the μ-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein. Mol. Pharmacol., 50, 1214-1222.
31. 1A receptor agonists in recombinant cell lines: Modulation of apparent efficacy by G-protein activation state. Naunyn-Schmiedeberg's Arch. Pharmarol., 356, 551-561.
32. PERT, C.B. & SNYDER, S.H. (1974). Opiate receptor binding of agonists and antagonists affected differentially by sodium. Mol. Pharmacol., 10, 868-879.
33. PUTTFARCKEN, P., WERLING, L., BROWN, S., COTE, T. & COX, B. (1986). Sodium regulation of agonist binding at opioid receptors. I. Effects of sodium replacement on binding at μ-and δ-type receptors in 7315c and NG108-15 cells and cell membranes. Mol. Pharmacol., 30, 81-89.
34. 35S]GTPγS binding in mMOR-CHO cells and rat thalamus. J. Pharmacol. Exp. Ther., 285,496-505.
35. 35S]GTPγS binding in rat thalamus and cultured cell lines: Signal transduction mechanisms underlying agonist efficacy. Mol. Pharmacol., 51, 87-96.
36. 35S]thio)triphosphate binding in rat brain: Evidence for partial agonist activity at mu opioid receptors. J. Neurochem., 70, 1567-1576.
37. 1 proteins: Effects of pertussis toxin. Mol. Endocrinol., 3, 1115-1124.
38. 35S]thio)triphosphate to NG108-15 cell membranes: Characterization of agonist and inverse agonist effects. J. Pharmacol. Exp. Ther., 283, 1276-1284.
39. TAO, Q. & ABOOD, M. (1998). Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J. Pharmacol. Exp. Ther., 285, 651-658.
40. THOMPSON, R.C., MANSOUR, A., AKIL, H & WATSON, S.J. (1993). Cloning and pharmacological characterization of a rat μ opioid receptor. Neuron. 11, 903-913.
41. 2-adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G protein state. Mol. Pharmacol., 45, 524-531.
42. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol., 47, 848-854.
43. WENZEL-SEIFERT, K., HURT, C. & SEIFERT, R. (1998). High constitutive activity of the human formyl peptide receptor. J. Biol. Chem., 273, 24181-24189.
44. 35S]guanosine-5′-O-(3-thio)-triphosphate binding: Agonist potencies and the influence of sodium chloride on intrinsic activity. Mol. Pharmacol., 51, 1060-1069.
45. YABALURI, N. & MEDZIHRADSKY, F (1997). Regulation of mu-opioid receptor in neural cells by extracellular sodium. J. Neurochem., 68, 1053-1061.
46. YU, V.C. & SADEE, W. (1988). Efficacy and tolerance of narcotic analgesics at the mu opioid receptor in differentiated human neuroblastoma cells. J. Pharmacol. Exp. Ther., 245, 350-355.